Impact of non-pharmacological strategies on progression in Parkinson’s Disease and Cognitive Impairment.
Objective: to determine the Impact of non-pharmacological strategies on progression in Parkinson's Disease and Cognitive Impairment. Background: PD is the second most common neurodegenerative disorder,…Clinical toolkits to improve conversations about Parkinson’s dementia
Objective: To co-produce, with people living with Parkinson’s and professionals, a pair of toolkits to improve conversations about Parkinson’s dementia in the clinic: one for…Correlation between dose of dopamine replacement therapy and King’s Parkinson’s Disease Pain Scale in Mexican Patients with Parkinson’s Disease
Objective: Investigate the relationship between the dose of dopamine replacement therapy (DRT) and pain severity as measured by the King's Parkinson's Disease Pain Scale (KPPS)…Association between dysphagia and body mass index and his impact on the severity of anxiety in patients with Parkinson Disease
Objective: To describe the relation between dysphagia and body mass index and the increase in anxiety and depression in patients with parkinson’s disease. Background: Parkinson’s…Movement disorders at the National Institute of Neurology and Neurosurgery (INNN, Mexico City): most common diagnoses during 2022.
Objective: To provide data about the movement disorders (MD) outpatient consultation (OC) service from the INNN, Mexico City during 2022. Background: The INNN, inaugurated in…Functional Neuroimaging and Follow up trends in Drug induced movement disorders.
Objective: To analyse the role of presynaptic dopaminergic imaging (TRODAT/ F Dopa PET) scans to predict long-term outcomes in patients of new onset parkinsonian symptoms…The phenotypic spectrum and assessment of severity in patients of Spinocerebellar Ataxia-12.
Objective: To describe clinical phenotype, manifestations, and assess tremor severity using standard rating scale in genetically confirmed patients with SCA12. Background: Spinocerebellar Ataxia-12 (SCA12) occurs…Quantification of Striatal and Extrastriatal Dopamine Transporters with [18F]PR04.MZ and [18F] PI- 2620 PET in Patients with Progressive Supranuclear Palsy.
Objective: We aim to evaluate the differences in striatal subregional dopamine transporter loss between Parkinson disease (PD) and progressive supranuclear palsy (PSP) of any stage…The role of genetic testing in Dystonia diagnosis
Objective: To determine the contribution of different approaches to the clinical use of genetic tests in dystonia diagnosis. Background: Dystonias are a heterogeneous group of…Dyspnea and quality of life in Parkinson’s: a mixed methods study
Objective: This study aimed to explore dyspnea experiences in people living with Parkinson’s PlwP who are walking independently. Background: Dyspnea is one of the non-motor…
- « Previous Page
- 1
- …
- 499
- 500
- 501
- 502
- 503
- …
- 1734
- Next Page »